Physicians perception in the management of allergic rhinitis: a Pan-India survey
Keywords:Allergic rhinitis, Anti-histamine, Bilastine, Leukotriene receptor antagonist, India
Background: Allergic rhinitis (AR) affects a wide proportion of the population across all age groups. There are several guidelines and consensus statements in AR management, the effect of this is implicit from a physician's perspective. The present cross-sectional survey was conducted to understand physicians approach to the management algorithm in the treatment of allergic rhinitis and medication choice.
Methods: Physicians from diverse specialties such as pulmonologists, consultant physician, paediatricians, Allergists, ENT specialists and general practitioners were invited to participate in the survey, which focused on recognizing the burden of disease, clinical presentation, and management methods.
Results: 1,261 Physicians participated in this survey, belonging to different specialties. Oral H1 antihistamine was favoured as a first-line therapy, followed by the combination of oral H1 histamine and leukotriene receptor antagonist. Fexofenadine was the most frequently prescribed. Majority believed, bilastine as antihistamine with the least sedative potential and was identified as the most effective treatment. Bilastine was preferred in patients with mild- moderate hepatic/renal impairment and in patients with persistent allergic rhinitis. Most physicians prefer bilastine in all AR clinical profiles. Aside from AR, bilastine is also use in management of upper respiratory tract infections and urticaria respectively.
Conclusions: AR is still a growing challenge in India with majority of physician preferring oral antihistamine either as monotherapy or in combination. Bilastine is a preferred choice in patients with impaired liver and renal function and was also referred as least sedative antihistamine by majority of physicians across India.
Canonica GW, Mullol J, Pradalier A, Didier A. Patient perceptions of allergic rhinitis and quality of life: findings from a survey conducted in Europe and the United States. World Allergy Organization Journal. 2008;1(9):138.
Egan M, Bunyavanich S. Allergic rhinitis: The “Ghost diagnosis” in patients with asthma. Asthma Res Pract. 2015;1:8.
Shah A, Pawankar R. Allergic Rhinitis and Co-morbid Asthma: Perspective from India- ARIA AsiaPacific Workshop Report. Asian Pacific Journal of Allergy And Immunology. 2009;27:71-77.
Wheatley LM, Togias A. Allergic Rhinitis Engl J Med. 2015;372(5):456-63.
Ciprandi G. Clinical utility and patient adherence with ebastine for allergic rhinitis. Patient preference and adherence. 2010;4:389.
Prabhat D, Sholapuri D, Uchit G. Physicians’ Perception on Allergic Rhinitis and Its Management: A Questionnaire Based Survey. Indian J Otolaryngol Head Neck Surg. 2019;71(3):2096-105.
Chandrika D. Allergic rhinitis in India: an overview. Int J Otorhinolaryngol Head Neck Surg. 2017;3:1-6.
Passalli D, Cingi C, Staffa P, Passali F, Muluk N, Bellussi ML. The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions. Asia Pac Allergy. 2018;8(1):e7.
Egan M, Bunyavanich S. Allergic rhinitis: the “Ghost Diagnosis” in patients with asthma. Asthma Research and Practice. 2015;1:8.
Burgess JA, Walters EH, Byrnes GB, Matheson MC, Jenkins MA, Wharton CL, et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. J Allergy Clin Immunol. 2007;120(4):863-9.
Mullol J. Positioning of antihistamines in the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines. Clinical & Experimental Allergy Reviews. 2012;12:17-26.
Bousquet J, Khaltaev N, Cruz AA. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy. 2008;63(86):8-160.
Jaggi V, Dalal A, Ramesh BR, Tikkiwal S, Chaudhary A, Kothari N et.a. Coexistence of allergic rhinitis and asthma in Indian patients: The CARAS survey. Lung India. 2019;36(5):411-16.
Mion ODG, de Mellor Jr, Dutra DL, Andrade NA, Almeida W, Anselmo-Lima. et.al. statement of the Brazilian Academy of Rhinology on the use of antihistamines, antileukotrienes, and oral corticosteroids in the treatment of inflammatory sinonasal diseases. Braz J Otorhinolaryngol. 2017;83(2):215-27.
Ciebiada M, Gorska Ciebiada M, Kmiecik T, DuBuske LM, Gorski P. Quality of Life in Patients With Persistent Allergic Rhinitis Treated With Montelukast Alone or in Combination With Levocetirizine or Desloratadine. J Investig Allergol Clin Immunol. 2008;18(5):343-49.
Kawauchi H , Yanai K, Wang DY , Itahashi K, Okubo K. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties. Int J Mol Sci. 2019;20:213.
García-Gea, C, Martínez-Colomer J, Antonijoan RM, Valiente R, Barbanoj MJ. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: A dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol. 2008;28:675-85.
Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009;64:158-65.
Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: A randomized, double-blind, parallelgroup study. Clin Exp Allergy. 2009;39:1338-47.
Okubo K, Gotoh M, Asako M, Nomura Y, Togawa M, Saito A.et.al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergol Int. 2017;66(1):97-105.
Bousquet J, Ansótegui I, Canonica GW, Zuberbier T, Baena-Cagnani CE, Bachert C, et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012;28(1):131-9.
Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodríguez M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet 2009;48:543-54.
Lasseter KC, Sologuren A, La Noce A, Dilzer SC. Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency. Clin Drug Investig (2013) 33:665-673.
Sastre J, Mullol J, Valero A, Valiente R. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis Curr Med Res Opin. 2012;28(1):121-30.